Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF suspension in rheumatoid arthritis remission maintenance
2016-003129-40Phase 4Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, certolizumab pegol, etanercept, infliximab and golimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Maintenance of clinical remission after anti-TNF suspension. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-003129-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003129-40.